Publications by authors named "F de Arriba"
This study examines the impact of cytogenetic abnormalities and their co-segregation on the prognosis of newly diagnosed multiple myeloma patients. The analysis included 1304 patients from four different GEM-PETHEMA clinical trials. Genetic alterations, such as t(4;14), t(14;16), del(17p), +1q, and del(1p), were investigated using FISH on CD38 purified plasma cells.
View Article and Find Full Text PDFImmunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease.
Ann Hematol
December 2024
Article Synopsis
- The study examined the impact of immunoparesis (IP) recovery on the prognosis of 113 newly diagnosed transplant-ineligible multiple myeloma (MM) patients who received a fixed treatment regimen and achieved complete or very good partial responses.
- Results showed that patients who initially had IP and then experienced recovery during or after treatment had significantly longer progression-free survival (PFS) and overall survival (OS) compared to those who did not recover.
- Additionally, among MRD negative patients, those with IP recovery also demonstrated improved PFS and OS, highlighting that IP recovery can enhance prognostic evaluations in combination with MRD status in this patient population.
Article Synopsis
- - In a study of 138 multiple myeloma (MM) patients, researchers explored the benefits of monitoring peripheral residual disease (PRD) in blood instead of relying solely on more invasive bone marrow (BM) assessments.
- - Positive PRD results from next-generation flow (NGF) indicated a significantly higher risk of disease progression/death, and those with undetectable PRD had excellent survival rates.
- - The findings suggest that PRD monitoring is a valuable and less cumbersome method for identifying patients at risk of relapse during maintenance treatment in transplant-eligible MM patients.
Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance.
J Clin Oncol
September 2024
Purpose: Early treatment of high-risk smoldering myeloma has been shown to delay progression to multiple myeloma (MM). We conducted this trial with curative intention using a treatment approach employed for newly diagnosed patients with MM.
Methods: Patients with high-risk smoldering myeloma (>50% progression risk at 2 years) and transplant candidates were included and received induction therapy with carfilzomib, lenalidomide, and dexamethasone (KRd), six cycles, followed by high-dose melphalan (200 mg/m) autologous stem-cell transplantation (HDM-ASCT), two KRd consolidation cycles, and Rd maintenance for 2 years.
The value of quantitative immunoprecipitation mass spectrometry (QIP-MS) to identify the M-protein is being investigated in patients with monoclonal gammopathies but no data are yet available in high-risk smoldering myeloma (HRsMM). We have, therefore, investigated QIP-MS to monitor peripheral residual disease (PRD) in 62 HRsMM patients enrolled in the GEM-CESAR trial. After 24 cycles of maintenance, detecting the M-protein by MS or clonal plasma cells by next-generation flow cytometry (NGF) identified cases with a significantly shorter median progression-free survival (mPFS) (MS: not reached vs.
View Article and Find Full Text PDF